Overview
- Dassault reported second-quarter revenue of €1.56 billion driven by subscription and cloud software growth and confirmed its full-year 2026 targets.
- The company agreed to acquire U.S.-based ArisGlobal for about $1.8 billion in cash plus up to $200 million tied to multi-year AI revenue targets.
- Dassault said the acquisition is intended to accelerate AI-enabled services for clinical development, regulatory submissions and pharmacovigilance and should be accretive to revenue and EPS in the first year after close.
- Dassault’s Life Sciences segment showed weakness in the quarter, with segment revenue down 4 percent and Medidata revenue down 3 percent, while industrial cloud sales rose 14 percent.
- The deal remains subject to regulatory approvals and is expected to close in the second half of 2026, a development that could reshape how drugmakers use AI for trials and safety monitoring and that investors will watch for integration progress and AI revenue performance.